Literature DB >> 10607703

Fibrinogen is a component of a novel lipoprotein particle: factor H-related protein (FHRP)-associated lipoprotein particle (FALP).

C T Park1, S D Wright.   

Abstract

We have previously described a novel lipoprotein particle consisting of phospholipids, apolipoprotein A-I (apoAI), lipopolysaccharide binding protein (LBP) and Factor H-related proteins (FHRP), and we termed these particles FALP (FHRP-associated lipoprotein particles). Highly purified preparations of FALP contain variable amounts of an unidentified polypeptide triplet of Mr approximately 85,000 (tp85). Here we report that tp85 represents fragment D of fibrinogen, as confirmed by N-terminal amino acid sequencing and Western blot analysis with an antifibrinogen antibody. The physical association of fibrinogen with other components of FALP in plasma was further confirmed by sandwich ELISA by using monoclonal antibodies against apoAI, FHRP or LBP to capture the particles and polyclonal antifibrinogen as the detecting antibody. Furthermore, affinity chromatography with anti-FHRP-1-specific IgG showed that fibrinogen is co-immunodepleted with FALP and approximately 17% of total plasma fibrinogen are bound to FALP. LBP is a lipid transfer protein that moves lipopolysaccharide (LPS) to a binding site on CD14 or high-density lipoprotein (HDL). To determine whether fibrinogen affects the lipid transfer activity of LBP on FALP, this activity was measured in FALP prepared with and without fibrinogen. Neither activity of LBP was affected by fibrinogen. The abundance of FALP suggests, instead, an effect of FALP on the function or clearance of fibrinogen or fragment D. (Blood. 2000;95:198-204)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10607703

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 2.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

Review 3.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

4.  Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi.

Authors:  Corinna Siegel; Teresia Hallström; Christine Skerka; Hannes Eberhardt; Barbara Uzonyi; Tobias Beckhaus; Michael Karas; Reinhard Wallich; Brian Stevenson; Peter F Zipfel; Peter Kraiczy
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

Review 5.  Lyme borreliosis spirochete Erp proteins, their known host ligands, and potential roles in mammalian infection.

Authors:  Catherine A Brissette; Anne E Cooley; Logan H Burns; Sean P Riley; Ashutosh Verma; Michael E Woodman; Tomasz Bykowski; Brian Stevenson
Journal:  Int J Med Microbiol       Date:  2008-01-11       Impact factor: 3.473

6.  Identification of fibrin clot-bound plasma proteins.

Authors:  Simone Talens; Frank W G Leebeek; Jeroen A A Demmers; Dingeman C Rijken
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

7.  Contribution of the infection-associated complement regulator-acquiring surface protein 4 (ErpC) to complement resistance of Borrelia burgdorferi.

Authors:  Claudia Hammerschmidt; Teresia Hallström; Christine Skerka; Reinhard Wallich; Brian Stevenson; Peter F Zipfel; Peter Kraiczy
Journal:  Clin Dev Immunol       Date:  2012-01-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.